Title

惡性淋巴瘤的生物治療進展

Translated Titles

Advancement of Biotherapy for Malignant Lymphoma

Authors

姜文奇(Wen-Qi Jiang)

Key Words

淋巴瘤 ; 生物療法 ; 美羅華/治療應用 ; Lymphoma ; Biotherapy ; Rituximab/therapeutic use

PublicationName

癌症

Volume or Term/Year and Month of Publication

24卷8期(2005 / 08 / 05)

Page #

1027 - 1032

Content Language

簡體中文

Chinese Abstract

近30年來,惡性淋巴瘤的發病率逐年上升,儘管它對化療非常敏感,新的化療藥物及化療方案也不斷湧現,但是其遠期生存率仍徘徊在40%~50%之間。近20年來,隨著免疫學的發展,生物治療在淋巴瘤治療中的地位正日益引起關注,並成為其綜合治療的重要組成部分。目前最常用於淋巴瘤治療的生物治療手段包括:(l)單克隆抗體的治療;(2)放射免疫治療;(3)抗原特異性CTL細胞(如EBV特異性T淋巴細胞)的過繼性免疫治療;(4)主動免疫治療;(5)靶向bcl-2的基因治療;(6)特異性小分子靶向藥物治療。合理使用這些方法並與其他治療手段有機地結合將有助於提高淋巴瘤的近期療效和遠期生存率。

English Abstract

In the past 30 years, the incidence of lymphoma was increasing. Although it is very sensitive to chemotherapy, and many new cytotoxic drugs and chemotherapy regimens have emerged, the 5-year survival rate of lymphome patients is only 40%-50%. With the development of immunology, the importance of biotherapy evoked more and more attention, and have became an important composition in the treatment of lymphoma. The most widely used biotherapy methods are listed as follows: monoclonal antibody, radioimmunotherapy, adoptive immunotherapy, active immunotherapy, gene therapy targeting Bcl-2, and targeted chemotherapy. Using these biotherapy methods in combination with other treatment methods reasonably will help to improve the short-term and long-term results of lymphoma.

Topic Category 醫藥衛生 > 內科